Navigation Links
BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
Date:2/18/2009

hree approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase 1 clinical development for the treatment of PKU. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the expectations of revenue and sales related to Naglazyme, Kuvan, and Aldurazyme; the financial performance of the BioMarin as a whole; the timing of BioMarin's clinical trials of 6R-BH4 for other indications, PEG-PAL, GALNS and other product candidates; the continued clinical development and commercialization of Aldurazyme, Naglazyme, Kuvan, and its product candidates; and actions by regulatory authorities. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: our success in the continued commercialization of Naglazyme and Ku
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. BioMarin to Host Fourth Quarter and Full Year 2008 Financial Results Conference Call and Webcast on Wednesday, February 18 at 5:00 p.m. ET (23:00 CET)
2. BioMarin to Present at the Piper Jaffray Healthcare Conference
3. BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer
4. BioMarin to Present at the Credit Suisse Healthcare Conference
5. BioMarin Announces Third Quarter 2008 Financial Results
6. BioMarin Corrects Information Included in Bloomberg Article
7. BioMarin to Present at the Merrill Lynch Global Pharmaceutical Conference
8. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
9. BioMarin to Present at the Citi Biotech Day
10. BioMarin Announces Roll-Out of National PKU Registry
11. BioMarin to Host Second Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, August 5 at 5:00 p.m. ET (23:00 CET)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Research and Markets  has announced the ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast ... http://photos.prnewswire.com/prnh/20130307/600769 Transfection is ... or RNA) into cells. This technology helps the cells ... protein metabolism by affecting the nuclear genes. The transfection ...
(Date:7/11/2014)... July 11, 2014 Cayenne Medical, ... specializing in the soft tissue reconstruction segment, announced ... System for surgeries involving the shoulder and extremities. ... a novel, inserter-controlled deployment method. The unique delivery ... deployment, anchor pull-out, or anchor displacement (also commonly ...
(Date:7/10/2014)... Terascala, the industry leader in ... a former vice president of product management for Flexera ... of marketing. Terascala’s software when combined with leading compute ... highest performance and most reliable solutions for processing big ... channel expansion and broaden its product portfolio. His leadership ...
(Date:7/10/2014)... July 10, 2014 Senior supply chain ... professional associations, addressed the challenges of “Reducing Cost, Lead ... Industries” through strategic sourcing. Describing the partnership of the ... Supply Chain Management Institute ( SCMI) of the ... June 24 at the Kroc Institute of Peace and ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Terascala Expands Executive Team 2Terascala Expands Executive Team 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4
... Fla., April 9 Cryo-Cell International, Inc. ... world,s largest and most established family cord blood banks, ... 28, 2009. Consolidated revenues for the first quarter ... approximately $4.2 million for the first quarter of fiscal ...
... the release of it,s advanced nutritional supplement, Caplex, ... a unique patent pending formulation created by ... provides cancer patients a comprehensive source of the ... on results accumulated from medical research. Impressive changes ...
... NANTONG, China, April 8 Sinobiopharma Pharmaceutical Group ... the appointment of Ms. Yan Tan as Director ... Co., Ltd., Netherlands. She served as a China-based ... sold to Schering-Plough. Prior to Organon, Ms. Tan ...
Cached Biology Technology:Cryo-Cell International, Inc. Reports First Quarter 2009 Results 2Cryo-Cell International, Inc. Reports First Quarter 2009 Results 3Cryo-Cell International, Inc. Reports First Quarter 2009 Results 4Cancer Fighting Nutrition Supplement, Caplex, Offers Cancer Patients A New All-Natural Treatment Option 2Sinobiopharma, Inc. Appoints New Director of Marketing 2
(Date:7/11/2014)... Shenzhen, July 10, 2014---A team of researchers from The ... have identified a gene of wild soybean linked to ... to grow in saline soil. This study published online ... to unveil novel genomic information for crop improvement. , ... to domestication and human selection, cultivated soybeans have less ...
(Date:7/11/2014)... Researchers have pioneered a revolutionary new way ... called Virtual Finger, allows scientists to move through ... synapses using the flat surface of their computer ... studies orders of magnitude more efficient, saving time, ... many areas of experimental biology. The software and ...
(Date:7/11/2014)... Evidence exists that cannabinoid receptor type 1 ... Ca2+ influx, and reduce neurotransmitter release. However, ... 1 can increase extracellular Ca2+ influx and ... his team, Tongji Hospital Affiliated to Tongji ... Technology, China used whole cell voltage-clamp and ...
Breaking Biology News(10 mins):BGI reports a novel gene for salt tolerance found in wild soybean 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
... Of Southern California School Of Dentistry have uncovered another clue ... leads to palate formation. Cleft palate is one ... out of every 700 live births. Clefts are more common ... males are twice as likely to have a cleft lip, ...
... record biometric revenues and profitability, WALL, N.J., ... BKYI), a leader in wireless public safety and,finger-based ... and strong revenue growth for its second quarter,ended ... operations for the quarter ended June 30,2008 was ...
... As people age, their cells become less efficient at ... of toxic material that is especially pronounced in Alzheimer,s, Parkinson,s ... first time, scientists at the Albert Einstein College of Medicine ... entire organ the liver and shown that, as ...
Cached Biology News:USC researchers identify alternate pathway that leads to palate development 2USC researchers identify alternate pathway that leads to palate development 3BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008 2BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008 3BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008 4BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008 5In scientific first, Einstein researchers correct decline in organ function associated with old age 2In scientific first, Einstein researchers correct decline in organ function associated with old age 3
Request Info...
Request Info...
Epi-Grids™ Colony Grid Templates are easy-to-use griding templates that allow rapid organization of colonies from initial screening plates and for preparing precise master plates....
Competitors to lower non-specific signal...
Biology Products: